Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DRI Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term. Geographically, it has a presence in the United States; European Union; Japan, and Rest of the world.


TSX:DHT.UN - Post by User

Post by retiredcfon Feb 11, 2024 9:14am
174 Views
Post# 35874337

Assessment

AssessmentYour thoughts on DRI Healthcare Trust please. I am reading outperform ratings in the Globe and Mail.

DHT.UN is a healthcare royalty investment company. Yield is 2.79% and valuation is quite low on a P/E basis. Market cap is $800M after a 13% gain already in 2024. High revenue growth is expected this year, but more muted EPS growth ($1.39 to $1.41). POW owns 20% of the company. We like its royalty portfolio, and last week the company upped its guidance in terms of expected capital deployment, to $1.25B over five years. This should (assuming good deals) set up good long term future cash flow. It is an interesting name in the (generally weak) Canadian healthcare space. It offers both income and growth potential, and should have some degree of stability. It is still a management bet on their ability to structure good deals, but so far, so good, in that regard. (5iResearch)
<< Previous
Bullboard Posts
Next >>